Wealth Enhancement Advisory Services LLC Purchases 6,213 Shares of Perrigo Company plc (NYSE:PRGO)

Wealth Enhancement Advisory Services LLC boosted its holdings in shares of Perrigo Company plc (NYSE:PRGO) by 41.5% in the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,181 shares of the company’s stock after purchasing an additional 6,213 shares during the period. Wealth Enhancement Advisory Services LLC’s holdings in Perrigo were worth $556,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in PRGO. Creative Planning raised its position in shares of Perrigo by 3.7% during the third quarter. Creative Planning now owns 18,477 shares of the company’s stock worth $485,000 after acquiring an additional 661 shares during the last quarter. Arizona State Retirement System grew its position in shares of Perrigo by 1.9% during the 2nd quarter. Arizona State Retirement System now owns 37,939 shares of the company’s stock worth $974,000 after buying an additional 699 shares during the period. Swiss National Bank raised its stake in shares of Perrigo by 0.3% during the first quarter. Swiss National Bank now owns 267,600 shares of the company’s stock worth $8,614,000 after buying an additional 800 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in Perrigo by 3.3% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 29,083 shares of the company’s stock valued at $747,000 after buying an additional 923 shares during the period. Finally, Texas Permanent School Fund Corp boosted its stake in Perrigo by 1.2% in the second quarter. Texas Permanent School Fund Corp now owns 119,298 shares of the company’s stock valued at $3,064,000 after acquiring an additional 1,357 shares during the last quarter. Institutional investors and hedge funds own 95.91% of the company’s stock.

Perrigo Stock Down 1.4 %

NYSE:PRGO opened at $26.93 on Friday. The stock has a market cap of $3.67 billion, a price-to-earnings ratio of -29.27 and a beta of 0.48. The company has a current ratio of 1.99, a quick ratio of 1.24 and a debt-to-equity ratio of 0.80. The stock has a 50-day moving average price of $26.19 and a two-hundred day moving average price of $27.52. Perrigo Company plc has a 1 year low of $23.89 and a 1 year high of $34.60.

Perrigo (NYSE:PRGO) last announced its earnings results on Wednesday, November 6th. The company reported $0.81 EPS for the quarter, hitting the consensus estimate of $0.81. The firm had revenue of $1.09 billion for the quarter, compared to the consensus estimate of $1.12 billion. Perrigo had a negative net margin of 2.81% and a positive return on equity of 6.79%. The business’s quarterly revenue was down 3.2% on a year-over-year basis. During the same period last year, the company posted $0.64 EPS. As a group, equities analysts expect that Perrigo Company plc will post 2.56 earnings per share for the current year.

Perrigo Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 17th. Shareholders of record on Friday, November 29th will be paid a $0.276 dividend. This represents a $1.10 annualized dividend and a yield of 4.10%. The ex-dividend date of this dividend is Friday, November 29th. Perrigo’s payout ratio is -119.57%.

Insiders Place Their Bets

In other news, Director Katherine C. Doyle sold 8,954 shares of the business’s stock in a transaction on Friday, September 13th. The shares were sold at an average price of $27.30, for a total value of $244,444.20. Following the sale, the director now owns 6,009 shares of the company’s stock, valued at $164,045.70. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, Director Katherine C. Doyle sold 8,954 shares of Perrigo stock in a transaction dated Friday, September 13th. The stock was sold at an average price of $27.30, for a total value of $244,444.20. Following the sale, the director now owns 6,009 shares of the company’s stock, valued at approximately $164,045.70. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Ronald Craig Janish sold 13,000 shares of the stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $29.40, for a total value of $382,200.00. Following the transaction, the executive vice president now directly owns 20,553 shares of the company’s stock, valued at $604,258.20. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 50,254 shares of company stock valued at $1,411,969 in the last quarter. 0.40% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

PRGO has been the subject of a number of analyst reports. Piper Sandler decreased their price objective on Perrigo from $36.00 to $35.00 and set an “overweight” rating for the company in a research note on Thursday, July 11th. Jefferies Financial Group restated a “hold” rating and set a $30.00 target price (down from $50.00) on shares of Perrigo in a research report on Monday, September 23rd. StockNews.com upgraded shares of Perrigo from a “hold” rating to a “buy” rating in a research report on Thursday. Finally, Canaccord Genuity Group reissued a “buy” rating and set a $42.00 price objective on shares of Perrigo in a research note on Monday, September 30th. One investment analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $37.00.

Perrigo Profile

Perrigo Company plc provides over-the-counter health and wellness solutions to enhance individual well-being in the United States, Europe, and internationally. It operates through Consumer Self-Care Americas and Consumer Self-Care International segments. The company develops, manufactures, markets, and distributes self-care consumer products, such as upper respiratory products, including cough suppressants, expectorants, and sinus and allergy relief; nutrition products consisting of infant formulas and nutritional beverages; digestive health products, including antacids, anti-diarrheal, and anti-heartburn; pain and sleep-aids products comprising pain relievers and fever reducers; and oral care products, which include toothbrushes, toothbrush replacement heads, floss, flossers, whitening products, and toothbrush covers.